A Study of PTC923 in Participants With Phenylketonuria
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05099640 |
|
Recruitment Status :
Completed
First Posted : October 29, 2021
Last Update Posted : May 23, 2023
|
Sponsor:
PTC Therapeutics
Information provided by (Responsible Party):
PTC Therapeutics
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The main purpose of this trial is to evaluate the efficacy of PTC923 in reducing blood phenylalanine (Phe) levels in participants with phenylketonuria as measured by mean change in blood Phe levels from baseline to Weeks 5 and 6 (that is, the average of each respective treatment dose 2-week period of double-blind treatment).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Phenylketonuria | Drug: PTC923 Drug: Placebo | Phase 3 |
The study includes 2 parts: Part 1 and 2. Part 1 of the study tests for responsiveness to PTC923, with 14 days of open-label treatment with PTC923. At the end of treatment in Part 1, the mean change in blood Phe levels over the 14-day treatment period for all participants will be assessed against their pretreatment (baseline) blood Phe level. Participants ≥2 years of age who experience a <15% reduction in blood Phe levels will be classified as non-responsive and participation in the study will be terminated. Participants (≥2 years of age) who experience a ≥15% reduction in blood Phe levels will continue into Part 2. Participants <2 years of age who experience ≥15% reduction in blood Phe levels will be offered the option to enroll directly into an open-label extension Study PTC923-MD-004-PKU. Participants <2 years of age who experience a <15% reduction in blood Phe levels will be classified as nonresponsive, and participation in the study will be terminated. Following the minimum 14-day PTC923 washout period, all eligible participants will be randomized in Part 2 to receive either PTC923 or placebo. After 6 weeks of treatment with either PTC923 or placebo, participants will be offered the option to enter an open-label extension Study PTC923-MD-004-PKU (NCT05166161).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 156 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3 Study of PTC923 in Subjects With Phenylketonuria |
| Actual Study Start Date : | September 30, 2021 |
| Actual Primary Completion Date : | April 3, 2023 |
| Actual Study Completion Date : | May 3, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Phenylketonuria
MedlinePlus related topics:
Phenylketonuria
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1: PTC923
Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg) (participants 0 to <6 months of age), 15 mg/kg (participants 6 to <12 months of age), 30 mg/kg (participants 12 months to <2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for 14 days.
|
Drug: PTC923
PTC923 powder for oral use will be suspended in water or apple juice prior to administration. |
|
Experimental: Part 2: PTC923
Participants will receive PTC923 20 mg/kg daily for Weeks 1 and 2, then PTC923 40 mg/kg daily for Weeks 3 and 4, then PTC923 60 mg/kg daily for Weeks 5 and 6.
|
Drug: PTC923
PTC923 powder for oral use will be suspended in water or apple juice prior to administration. |
|
Placebo Comparator: Part 2: Placebo
Participants will receive equivalent quantities of placebo to match the 20 to 40 to 60 mg/kg dose escalation of the PTC923 treatment arm.
|
Drug: Placebo
Placebo matching to PTC923 |
Primary Outcome Measures :
- Change From Baseline in Phe Levels at Part 2 Weeks 5 and 6 [ Time Frame: Baseline, Weeks 5 and 6 (average of the 2-week period) ]Baseline blood Phe level will be the mean of Day -1 and Day 1 (predose) blood Phe levels.
Secondary Outcome Measures :
- Percentage of Participants With Baseline Phe Levels ≥600 micromoles (μmol)/liter (L) who Achieved Phe Levels <600 μmol/L at the End of the Double-Blind Treatment Period [ Time Frame: Baseline to Week 6 ]
- Change From Baseline in Mean Blood Phe Levels at Each PTC923 Dose Level (Average of the Each 2-Week Period in Part 2) [ Time Frame: Baseline, Weeks 1 and 2, Weeks 3 and 4, and Weeks 5 and 6 ]Baseline blood Phe level will be the mean of Day -1 and Day 1 (predose) blood Phe levels.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Uncontrolled blood Phe level ≥360 μmol/L on current therapy anytime during screening and uncontrolled blood Phe level ≥360 μmol/L on current therapy when taking the average of the 3 most recent Phe levels from the participant's medical history (inclusive of the screening value).
- Clinical diagnosis of phenylketonuria with hyperphenylalaninemia (HPA) documented by past medical history of at least 2 blood Phe measurements ≥600 μmol/L.
- Women of childbearing potential must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for up to 90 days after the last dose of study drug.
- Males who are sexually active with women of childbearing potential who have not had a vasectomy must agree to use a barrier method of birth control during the study and for up to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period.
- Willing to continue current diet unchanged while participating in the study.
Exclusion Criteria:
- Gastrointestinal disease (such as irritable bowel syndrome, inflammatory bowel disease, chronic gastritis, and peptic ulcer disease, etc.) that could affect the absorption of study drug.
- History of gastric surgery, including Roux-en-Y gastric bypass surgery or an antrectomy with vagotomy, or gastrectomy.
- History of allergies or adverse reactions to synthetic tetrahydrobiopterin (BH4) or sepiapterin.
- Current participation in any other investigational drug study or use of any investigational agent within 30 days prior to screening.
- Any clinically significant laboratory abnormality as determined by the investigator.
- A female who is pregnant or breastfeeding, or considering pregnancy.
- Serious neuropsychiatric illness (for example, major depression) not currently under medical control, that in the opinion of the investigator or sponsor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.
- Past medical history and/or evidence of renal impairment and/or condition including moderate/severe renal insufficiency (glomerular filtration rate [GFR] <60 milliliters [mL]/minute [min]) and/or under care of a nephrologist.
- Any abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated GFR <60 mL/min/1.73 square meter (m^2).
- Requirement for concomitant treatment with any drug known to inhibit folate synthesis (for example, methotrexate).
- Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive guanosine-5'-triphosphate (GTP) cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin-4-alpha-carbinolamine dehydratase genes.
- Major surgery within the prior 90 days of screening.
- Concomitant treatment with BH4 supplementation (for example, sapropterin dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ).
- Unwillingness to washout from BH4 supplementation (for example, sapropterin dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05099640
Locations
Show 43 study locations
Sponsors and Collaborators
PTC Therapeutics
| Responsible Party: | PTC Therapeutics |
| ClinicalTrials.gov Identifier: | NCT05099640 |
| Other Study ID Numbers: |
PTC923-MD-003-PKU 2021-000474-29 ( EudraCT Number ) |
| First Posted: | October 29, 2021 Key Record Dates |
| Last Update Posted: | May 23, 2023 |
| Last Verified: | May 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Phenylketonurias Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |